Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: From benchside to clinical use

Giuseppe Aprile, Marta Bonotto, Elena Ongaro, Carmelo Pozzo, Francesco Giuliani

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or early appearance of resistance mechanisms, and the lack of predictive factors for treatment selection. Recent data suggest that antibodies targeting the vascular endothelial growth factor axis exert their activity through the inhibition of vascular endothelial growth factor receptor-2 phosphorylation, which has a pivotal role in the neoangiogenic process. Ramucirumab, a fully humanized monoclonal antibody specifically directed against the extracellular domain of the receptor, administered intravenously every 2 or 3 weeks, is emerging as a novel antiangiogenic opportunity. Starting with preclinical data and early clinical results, this concise review focuses on the development of the novel compound across multiple cancers (including gastrointestinal malignancies, breast cancer, lung carcinoma, and genitourinary tumors), and presents available data from randomized phase II and phase III trials. REGARD was the first phase III study to report on the efficacy of single-agent ramucirumab in patients with advanced cancer. Many other ongoing phase III trials are testing the efficacy of this interesting antiangiogenic compound as a single agent or in combination with chemotherapy in different cancer types.

Original languageEnglish
Pages (from-to)2003-2015
Number of pages13
JournalDrugs
Volume73
Issue number18
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Neoplasms
Therapeutics
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor Receptor-2
Gastrointestinal Neoplasms
Proxy
Combination Drug Therapy
Vascular Endothelial Growth Factor A
Lung Neoplasms
Phosphorylation
ramucirumab
Breast Neoplasms
Carcinoma
Survival
Antibodies

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment : From benchside to clinical use. / Aprile, Giuseppe; Bonotto, Marta; Ongaro, Elena; Pozzo, Carmelo; Giuliani, Francesco.

In: Drugs, Vol. 73, No. 18, 12.2013, p. 2003-2015.

Research output: Contribution to journalArticle

Aprile, Giuseppe ; Bonotto, Marta ; Ongaro, Elena ; Pozzo, Carmelo ; Giuliani, Francesco. / Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment : From benchside to clinical use. In: Drugs. 2013 ; Vol. 73, No. 18. pp. 2003-2015.
@article{189659ff44c24a5aae07f5a2941a5cd8,
title = "Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: From benchside to clinical use",
abstract = "Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or early appearance of resistance mechanisms, and the lack of predictive factors for treatment selection. Recent data suggest that antibodies targeting the vascular endothelial growth factor axis exert their activity through the inhibition of vascular endothelial growth factor receptor-2 phosphorylation, which has a pivotal role in the neoangiogenic process. Ramucirumab, a fully humanized monoclonal antibody specifically directed against the extracellular domain of the receptor, administered intravenously every 2 or 3 weeks, is emerging as a novel antiangiogenic opportunity. Starting with preclinical data and early clinical results, this concise review focuses on the development of the novel compound across multiple cancers (including gastrointestinal malignancies, breast cancer, lung carcinoma, and genitourinary tumors), and presents available data from randomized phase II and phase III trials. REGARD was the first phase III study to report on the efficacy of single-agent ramucirumab in patients with advanced cancer. Many other ongoing phase III trials are testing the efficacy of this interesting antiangiogenic compound as a single agent or in combination with chemotherapy in different cancer types.",
author = "Giuseppe Aprile and Marta Bonotto and Elena Ongaro and Carmelo Pozzo and Francesco Giuliani",
year = "2013",
month = "12",
doi = "10.1007/s40265-013-0154-8",
language = "English",
volume = "73",
pages = "2003--2015",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "18",

}

TY - JOUR

T1 - Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment

T2 - From benchside to clinical use

AU - Aprile, Giuseppe

AU - Bonotto, Marta

AU - Ongaro, Elena

AU - Pozzo, Carmelo

AU - Giuliani, Francesco

PY - 2013/12

Y1 - 2013/12

N2 - Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or early appearance of resistance mechanisms, and the lack of predictive factors for treatment selection. Recent data suggest that antibodies targeting the vascular endothelial growth factor axis exert their activity through the inhibition of vascular endothelial growth factor receptor-2 phosphorylation, which has a pivotal role in the neoangiogenic process. Ramucirumab, a fully humanized monoclonal antibody specifically directed against the extracellular domain of the receptor, administered intravenously every 2 or 3 weeks, is emerging as a novel antiangiogenic opportunity. Starting with preclinical data and early clinical results, this concise review focuses on the development of the novel compound across multiple cancers (including gastrointestinal malignancies, breast cancer, lung carcinoma, and genitourinary tumors), and presents available data from randomized phase II and phase III trials. REGARD was the first phase III study to report on the efficacy of single-agent ramucirumab in patients with advanced cancer. Many other ongoing phase III trials are testing the efficacy of this interesting antiangiogenic compound as a single agent or in combination with chemotherapy in different cancer types.

AB - Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or early appearance of resistance mechanisms, and the lack of predictive factors for treatment selection. Recent data suggest that antibodies targeting the vascular endothelial growth factor axis exert their activity through the inhibition of vascular endothelial growth factor receptor-2 phosphorylation, which has a pivotal role in the neoangiogenic process. Ramucirumab, a fully humanized monoclonal antibody specifically directed against the extracellular domain of the receptor, administered intravenously every 2 or 3 weeks, is emerging as a novel antiangiogenic opportunity. Starting with preclinical data and early clinical results, this concise review focuses on the development of the novel compound across multiple cancers (including gastrointestinal malignancies, breast cancer, lung carcinoma, and genitourinary tumors), and presents available data from randomized phase II and phase III trials. REGARD was the first phase III study to report on the efficacy of single-agent ramucirumab in patients with advanced cancer. Many other ongoing phase III trials are testing the efficacy of this interesting antiangiogenic compound as a single agent or in combination with chemotherapy in different cancer types.

UR - http://www.scopus.com/inward/record.url?scp=84892572924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892572924&partnerID=8YFLogxK

U2 - 10.1007/s40265-013-0154-8

DO - 10.1007/s40265-013-0154-8

M3 - Article

C2 - 24277700

AN - SCOPUS:84892572924

VL - 73

SP - 2003

EP - 2015

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 18

ER -